Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Inovio Pharmaceuticals shares rose 12.1% in pre-market trading after securing Orphan Drug Designation for INO-3107 from the European Commission for the treatment of recurrent respiratory papillomatosis. Other pre-market gainers include Minerva Surgical, EpicQuest Education Group, and Unique Fabricating, while losers include CohBar, PTC Therapeutics, and WISeKey International Holding.
May 24, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inovio Pharmaceuticals shares rose 12.1% in pre-market trading after securing Orphan Drug Designation for INO-3107 from the European Commission for the treatment of recurrent respiratory papillomatosis.
The Orphan Drug Designation for INO-3107 is a positive development for Inovio Pharmaceuticals, as it provides regulatory and financial incentives for the development of the drug. This news is likely to boost investor confidence in the company's pipeline and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100